Sera Prognostics Inc (Sera Prognostics) is a biotechnology firm, that specializes in providing diagnostic tests for predicting the risk of pregnancy complications such as premature birth and preeclampsia. It offers PreTRM, a proteomic predictor of premature birth risk for clinicians, mothers and doctors to deliver personalized care plans and treatments for improving the newborn and maternal health. The company’s biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression. Sera Prognostics is headquartered in Salt Lake, Utah, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Sera Prognostics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Sera Prognostics Inc Company Overview
- Sera Prognostics Inc Company Snapshot
- Sera Prognostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Sera Prognostics Inc - Pipeline Analysis Overview
- Sera Prognostics Inc - Key Facts
- Sera Prognostics Inc - Major Products and Services
- Sera Prognostics Inc Pipeline Products by Development Stage
- Sera Prognostics Inc Pipeline Products Overview
- Biomarker Test - Fetal Growth Restriction
- Biomarker Test - Fetal Growth Restriction Product Overview
- Biomarker Test - Gestational Diabetes Mellitus
- Biomarker Test - Gestational Diabetes Mellitus Product Overview
- Biomarker Test - Molecular Time-to-Birth
- Biomarker Test - Molecular Time-to-Birth Product Overview
- Biomarker Test - Postpartum Depression
- Biomarker Test - Postpartum Depression Product Overview
- Biomarker Test - Stillbirth
- Biomarker Test - Stillbirth Product Overview
- Diagnostic Test - Preeclampsia
- Diagnostic Test - Preeclampsia Product Overview
- Predictive Analytics Test
- Predictive Analytics Test Product Overview
- Pregnancy Risk Prediction Panel
- Pregnancy Risk Prediction Panel Product Overview
- Sera Prognostics Inc - Key Competitors
- Sera Prognostics Inc - Key Employees
- Sera Prognostics Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Sera Prognostics Inc, Recent Developments
- Dec 04, 2024: Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
- Jul 25, 2024: Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024
- Jul 09, 2024: Sera Prognostics PreTRM Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
- Oct 25, 2023: Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023
- May 22, 2023: Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue
- Feb 16, 2023: Sera Prognostics reports data from PreTRM test trial
- Nov 29, 2022: Fors Marsh to include the Pretrm Test in its employee maternity benefits package in collaboration with Sera Prognostics
- Nov 15, 2022: Sera Prognostics announces publication of data predicting clinical utility and cost effectiveness of the PreTRM test-and-treat strategy across diverse populations
- Oct 04, 2022: Sonrava Health to include the PreTRM test in its employee maternity benefits package in collaboration with Cerebrae and Sera Prognostics
- Sep 22, 2022: Banner Health, Sera Prognostics Team Up to Provide PreTRM Test to Covered Pregnant Members
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Sera Prognostics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Sera Prognostics Inc Pipeline Products by Equipment Type
- Sera Prognostics Inc Pipeline Products by Indication
- Sera Prognostics Inc, Key Facts
- Sera Prognostics Inc, Major Products and Services
- Sera Prognostics Inc Number of Pipeline Products by Development Stage
- Sera Prognostics Inc Pipeline Products Summary by Development Stage
- Biomarker Test - Fetal Growth Restriction - Product Status
- Biomarker Test - Fetal Growth Restriction - Product Description
- Biomarker Test - Gestational Diabetes Mellitus - Product Status
- Biomarker Test - Gestational Diabetes Mellitus - Product Description
- Biomarker Test - Molecular Time-to-Birth - Product Status
- Biomarker Test - Molecular Time-to-Birth - Product Description
- Biomarker Test - Postpartum Depression - Product Status
- Biomarker Test - Postpartum Depression - Product Description
- Biomarker Test - Stillbirth - Product Status
- Biomarker Test - Stillbirth - Product Description
- Diagnostic Test - Preeclampsia - Product Status
- Diagnostic Test - Preeclampsia - Product Description
- Predictive Analytics Test - Product Status
- Predictive Analytics Test - Product Description
- Pregnancy Risk Prediction Panel - Product Status
- Pregnancy Risk Prediction Panel - Product Description
- Sera Prognostics Inc, Key Employees
- Glossary
- Sera Prognostics Inc Pipeline Products by Equipment Type
- Sera Prognostics Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- VolitionRX Ltd
- Reflect Scientific, Inc.
- ClearPoint Neuro Inc
